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ontraceptives: Nature, Use

And Physiological Effects*
ANNE

R.

MALEDON,

"Within a few years 80 million women on
this continent alone will be taking 'the
pill'!"
John Gillies, Medical World

Approximately 5,000,000 Ameri
can women are now using oral
contraceptives. "Never have so many
people taken such potent drugs vol
untarily over such a protracted pe
riod for an objective other than the
control of disease. "1 So spoke a spe
cial advisory committee of the U.S.
Food and Drug Administration.
But is "the pill" safe to take? To
this question came the answer: "The
committee finds no adequate scien
tific data, at this time, proving these
compounds unsafe for human use."2
The tone of reservation implicit in
the double negative of the statement
is not surprising. Even without
reading the Time magazine report,
a non-professional layman knows
that medicines "cannot be certified
as completely safe until after years
of detailed study on tens of thou
sands of patients."3 And even then
certification can be valid only if
large scale, careful reporting is
adhered to.
As "the pill" moves into its second
decade of consumption, however,
* Revision of a student paper directed by
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interest in it grows apace.
b er of aspects, particul£ ,, the
moral and socio-economic, :e in
triguing. But this paper c ls ex
elusively w ith the natl ' use,
and physiological effects , oral
contraceptives.
NATURE

All oral contraceptives consist
basically of two synthetic .eroids,
an estrogen and a progestc 'n. Selection of one of two
rithetic
gestoestrogens and one of ten
gens accounts for the trad names.
If the two steroids are adrr 1istered
together for twenty days, · e ther
apy is called combinatior If an
estrogen is given for fiftE. 1 days,
then a progestogen for the tst five,
the therapy is called sequen· il. 4 The
combined steroids are Jld as
Enovid (the original "pill" Ortho
N ovum, Norinyl, Prov, .t, and
Norlestin. The estrogen-pr< ;estogen
composite goes by the r· :mes of
Oracon and C-Quens, br h mor e
recently developed drugs. 1 ,e diff�r
ence? Theoretically, the s-·quenual
therapy resembles the secr..:tion se
quence as it occurs in t,1e body.
Practically, however, neithLr ty pe of
therapy replicates the natvral proc
ess of secretion of the sex horm ones,
nor are all the synthetic ster oids
chemically identical with the natural
steroid hormones of either class. In
efficacy and general side effects,
none the less, the combined and
sequential forms are similar.
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not occur. R L. Holmes in the
"The pill," composed of synthetic journal Lancet, states a different
steroids, has several uses. Paradoxi opinion, namely, that LH release is
cally, it is employed for both con not blocked, and that suppression
ceptive and contraceptive purposes. of FSH has neither been proved nor
As a contraceptive agent, it is un disproved.6 Experiments with ani
questionably effective. In fact, its mals do indicate that ovulation is
99+% efficiency rate is becoming a suppressed, but since ovulation in
dictum. Over and above their effi animals is not identical with that of
cacy as contraceptives, "the pills" women, what may be true of
have proved remedial for gyneco animals is not necessarily true of
logical orders. Irregular menses, humans, in this regard. Other
amenorrhea, dysmenorrhea, endo investigators .have suggested other
metrios.is, and menopausal complaints mechanisms by which oral con
are some of these. Obviously, it will traceptives may produce functional
be some time before the overall ther sterility (There is some evidence
apeutic value of "the pills" is estab of permanent sterility, incidentally,
lished. Even so, oral contraceptives which may work a hardship for
to date have been an important those women who plan to have
children after a year or two on
medical tool.
"the pill"). These mechanisms may
PHYSIOLOGICAL EFFECTS
be either a direct influence on the
Ironically, despite their 99+% ovary, or a deleterious action on the
effectiveness when taken as directed germ cells themselves.7, 8
the mode of action of oral contra�
ceptives is littl� understood. Author
Whatever the uncertainty regard
ities are certain of only the obvious: ing the mode of action of "the pills,"
· that administered daily from the their influence on the body's natural
fifth through the twenty-fourth day hormone balance is well known.
of the menstrual cycle, "the pill" The estrogen-progestogen combina
will prevent conception and produce tions taken daily lead also to altera
an artificial menstrual period re tions of the harmonics of several
sembling the natural one in both other systems including the neuro
duration and quantity of flow.
logical, which are concerned in
reproductive and behavioral physi
Many authorities believe that ovu
ology.9 Experiments with estrogen
lation is prevented. In support of progestogen i n animals a l s o
this view, Edwin DeCosta, writing demonstrate that pituitary tumors
in ].A.M.A., postulates that the two are frequently found after prolonged
hormones in "the pill" suppress ovu treatment.
lation by acting on the pituitary
5
The most obvious effects of these
�land. "The pill" inhibits the pitu
itary from secreting the gonado contraceptive agents, however, is a
trophic hormones, FSH and LH. local one, i.e., the radical change
Since these two hormones are not produced in the endometrium. In
secreted, the egg is not "prepared" contrast to a normal endometrium,
for ovulation, and the process does characterized by vascular tissue
NOVEMBER, 1966
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supplied with many glands, the
progestogen-treated endometrium ex
h i b i t s only a f e w i n volute d
glands, poor vascularity, and stromal
edema.1° Collectively, these changes
produce the appearance of aging of
the endometrium. 11 Although neo
plastic relationships as such will be
dealt with later on in this paper,
attention should be called here to
the observation that "in predisposed
individuals, the unopposed action of
estrogenic substances - and all oral
contraceptives are estrogenic- for
considerable periods of time will re
sult in endometrial adenomatous
hyperplasfa, carcinoma in situ, and
eventually in carcinoma."12
Over and above the influence of
oral contraceptives on the endocrine
and other systems in · general, and
the uterine lining in particular, their
action is associated with liver dam
age. The estrogen component of "the
pill" is known to impair the excre
tory function of the liver; it may
damage liver cells directly.rn Tests
generally employed in medical prac
tice to detect hepatic impairment
are I) serum transaminase level,
2) bromsulphthalein retention, 3)
serum alkaline phosphatase levels.
Abnormally high serum transami
nase levels and bromsulphthalein
retention appear in almost every
tested user of "the pill."14, 15 , 16, 1 1
Stroll noted an increase in serum
transaminase from the normal I0-40
units to 200 units, and in serum iso
citric dehydrogenase levels from the
normal 3-10 units to 77-165 units.ts
Bromsulphthalein retention has been
known to increase to pathological
levels within two weeks during "pill"
use. Hepatic malfunction may de362

velop in as few as 28 days,
cycle of treatment.

)ne

In 1963, Enovid was bn ght
under criticism for its susf �ted
relationship with thromboembc ;sm.
This is not astonishing, for thrc 1bo
embolism has been associate vith
pregnancy, during which time 1igh
concentrations of estrogens an, pro
gestins appear in the blood. lhat
brought "the pill" to mm idity
headlines, however, was the �port
that more than 350 cases of t rom
boembolism had occurred in I 10vid
users in little over a twelve .onth
period. At this point, the FI \ ap
pointed the Wright Commi 2e to
investigate these cases; the c, ,1mit
tee reported its findings l; �r in
1963. Wright and his work1 s tal
lied a 12.1 % incidence r fatal
thromboemboli among Enovi users,
as compared with the 8.4% ate in
the general population. 19 1 ,e fig
ures became statistically rn1 e sig
nificant when age group were
considered. In women use s who
were over thirty-five, there was a
disproportionately greater ir ;idence
of thromboembolism. Usi.:g the
same statistics as Wright, � assouf
calculated fatality rates on ,, differ
ent basis. He used "woma1,-years"
(twelve women taking the drug for
one month each) as the unit of
exposure. This was the basis on
which most of the favorable statistics
on Enovid had been calculated.
According to Kassouf's calculations,
the death rate from thromboembo
lism was 22.3 per million per
year, nearly three times as high as
that in the population at large.20
No t w i t hs t a n di ng, t he Wri gh t
Committee concluded that a defi LINACRE QUARTERLY

nite cause-effect relationship between
"the pill" and thromboemboli is yet
to be statistically demonstrated. Still
to be demonstrated, however, is the
absence of cause and effect correla
tion between "pill" and clot. In the
interim, though, it is not irrelevant
to note that oral progestins are being
used in the treatment of hemorrhagic
disorders.2l
A second circulatory phenomenon
observed in "the pill" users is an
increased venous distensibility simi
lar to that observed in pregnancy.
Over a period of time, the valves
which prevent the backflow of blood
become incompetent, and allow the
blood to stagnate in the vessels,
thereby providing opportune envi
ronment for thrombophlebitis and/or
thromboemboli. As Eugene F. Dia
mond points out, even those who
disagree on the association between
"the pill" and thromboemboli,
"fairly uniformly admit the associa
tion between oral progestins and
thrombophlebitis."22 And how many
cardiovascular specialists would deny
that thrombophlebitis at least pre
disposes vessels to the formation of
clots?
Finally, estrogenic agents, even
naturally occurring ones, have been
known since the turn of the century
to be associated with malignancies.
To what extent malignant neo
plasms are effected or affected by
estrogens depends in part upon·
the type of neoplasm23 · 24 and the
amount of estrogen administered. 2;;
In certain predisposed humans and
research animals, estrogen has been
known to "cause" cancer . This is
usually a gradual process, which
begins with the alteration of the
NOVEMBER,
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hormone balance, which in turn
produces cellular changes in the
ovary or other parts of the body,
and eventually ends with tumors.26
A much more common concomitant
of estrogen therapy, however, is a
pronounced growth of already exist
ing tumors. Very small breast car
cinomas have developed with great
rapidity during oral contraceptive
use, according to Shipman.27 More
over, the progestogen component of
"the pill" ma,y increase metastasis
of an initially localized malignancy.28
Above and beyond the major ill
effects so far mentioned, oral con
traceptives may induce so-called
minor side-effects: 29 , 30, 31 , 32 l) break
through bleeding or "spotting," 2)
nausea; 3) weight-gain - up to ten
pounds, 4) breast soreness and en
largement, 5) acne, 6) headache, 7)
dizziness, 8) depression and fatigue,
9) irritability, IO) edema, 11) aug
mented pre-menstrual tension, 12)
stoppage of lactation, 13) insomnia,
14) increased facial pigmentation,
IS) leg cramping, 16) rash/itching,
17) amenorrhe'a, 18) loss or growth
of body hair, 19) 'growth of uterine
fibroids, 20) virilization of the fe
male infant. Many of these are, ad
mittedly, more disagreeable than
dangerous. A few, however, carry
a subtle threat. Two of these only
will be treated here.
First, break-through or intermens
trual bleeding. Under ordinary con
ditions, unusual bleeding may be
symptomatic of malignancy. Since,
however, spotting is to be expected
during oral contraceptive use, both
patient and doctor may dismiss such
bleeding as unimportant. G. H.
Green highlights the danger latent
363

in such a dismissal: a young woman
of thirty had complained of spotting
while taking "the pill." The attend
ing physician had attached no sig
nificance to the event, because the
woman had had a cervical smear
within the year. That six months
later she was found to have a far
advanced malignancy33 would seem
to be somewhat alarming.
The second side-effect deserving
special comment is virilization of the
female infant. Not always, but fre
quently enough, oral contraceptives
taken during the early months of
pregnancy affect the female foetus.
The masculinizing effect is usually
in the form of an enlarged clitoris,
of which the implications for the
child's future may be more than
incidental.
Having come this far, let us take
a backward glance at these data on
"the pills." They are effective as
contraceptives to the extent of almost
100%. They are useful as gyneco
logical tools. Such is medical con
sensus about their efficacy. About
their safety, however, there is not
such unanimity. Even so, suppose
that all the side-effects, major and
minor, are later obviated. What will
be the results of long term - a pos
sible thirty years34 - alteration of
human female metabolic rhythms?
Of the disruption of the delicate
and dynamic body equilibrium
which physiologists have so long
sought to understand and to pre
serve? Perhaps not even time will tell.
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